Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial

Autor: Romain Guièze, Loïc Ysebaert, Damien Roos-Weil, Luc-Mathieu Fornecker, Emmanuelle Ferrant, Lysiane Molina, Thérèse Aurran, Aline Clavert, Sophie de Guibert, Anne-Sophie Michallet, Alain Saad, Bernard Drénou, Philippe Quittet, Bénédicte Hivert, Kamel Laribi, Julie Gay, Anne Quinquenel, Julien Broseus, Valérie Rouille, David Schwartz, Benoit Magnin, Grégory Lazarian, Lauren Véronèse, Marie de Antonio, Camille Laurent, Olivier Tournilhac, Bruno Pereira, Pierre Feugier

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-8 (2024)

Abstract Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubic

Externí odkaz: https://doaj.org/article/d8209fe8dc6b44468c1e39a38312227a

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Autor: Anne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Therese Aurran-Schleinitz, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Véronique Leblond, Marie-Sarah Dilhuydy, Caroline Dartigeas, Cecile Tomowiak, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stephane Lepretre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen Khac, Valérie Rouille, Alain Delmer, Anne-Sophie Michallet

Publikováno v: Blood. 140:7007-7009

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6ba0566023d75cb26485ddef03bbb9fd
https://doi.org/10.1182/blood-2022-159678

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Autor: Anne Banos, Vincent Levy, Magali Le Garff-Tavernier, Veronique Leblond, Sophie de Guibert, Valérie Rouille, Loic Ysebaert, Philippe Carassou, Bruno Villemagne, Kamel Laribi, Alain Delmer, Frederique Orsini, Beatrice Mahe, Michel Ticchioni, Gilles Salles, Marie-Sarah Dilhuydy, Thérèse Aurran, Carmen Aanaei, Florence Nguyen-Khac, Brigitte Pegourie, Rémi Letestu, Fabien Subtil, Luc Mathieu Fornecker, Caroline Dartigeas, Jean Pierre Vilque, Cécile Tomowiak, Guillaume Cartron, Florence Cymbalista, Margot Truchan, Anne-Sophie Michallet, Christelle Portois, Pierre Feugier, Olivier Tournilhac, Stéphane Leprêtre

Publikováno v: 61st Annual Meeting and Exposition of the American Society of Hematology
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.3038, 2019, Blood

Introduction In previously untreated, medically fit patients with chronic lymphocytic leukaemia (CLL) and no 17p deletion, there is current research interest in improving survival outcomes and potentially sparing some patients from the standard 6 cyc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3706e3de4100c82389c2049419a95dfb
https://hal.archives-ouvertes.fr/hal-02427562

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Autor: Romain Guieze, Loic Ysebaert, Damien Roos-Weil, Lysiane Molina, Luc Mathieu Fornecker, Thérèse Aurran, Anne-Sophie Michallet, Emmanuelle Ferrant, Aline Clavert, Alain Saad, Sophie de Guibert, Bernard Drenou, Philippe Quittet, Bénédicte Hivert, Kamel Laribi, Julie Gay, Julien Broséus, Valérie Rouille, David Schwartz, Bruno Pereira, Alain Delmer, Pierre Feugier

Publikováno v: Blood. 138:3570-3570

Background Richter syndrome (RS) refers to the onset of aggressive lymphoma, mostly diffuse large B cell lymphoma (DLBCL), in patients with chronic lymphocytic leukemia (CLL). The outcome of RS patients is usually very poor with both low response rat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::96bf04683daad690b75bf445be2a3c65
https://doi.org/10.1182/blood-2021-147467

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial

Autor: Carmen Aanei, Florence Nguyen-Khac, Luc Mathieu Fornecker, Marie-Sarah Dilhuydy, Anne Banos, Olivier Tournilhac, Stéphane Leprêtre, Anne-Sophie Michallet, Loic Ysebaert, Thérèse Aurran, Christelle Portois, Jean Pierre Vilque, Cécile Tomowiak, Veronique Leblond, Caroline Dartigeas, Pierre Feugier, Guillaume Cartron, Philippe Carassou, Rémi Letestu, Bruno Villemagne, Gilles Salles, Florence Cymbalista, Fabien Subtil, Vincent Levy, Kamel Laribi, Beatrice Mahe, Malgorzata Truchan Graczyk, Alain Delmer, Frederique Orsini, Brigitte Pegourie, Magali Le Garff-Tavernier, Michel Ticchioni, Sophie de Guibert, Valérie Rouille

Publikováno v: The Lancet Haematology
The Lancet Haematology, Elsevier, 2019, 6 (9), pp.e470-e479. ⟨10.1016/S2352-3026(19)30113-9⟩

In patients with chronic lymphocytic leukaemia, achievement of a complete response with minimal residual disease of less than 0·01% (ie,1 chronic lymphocytic leukaemia cell per 10 000 leukocytes) in bone marrow has been associated with improved prog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5113ceb78b12a9741b47cccce2975352
https://pubmed.ncbi.nlm.nih.gov/31324601